AbbVie Inc. $ABBV Shares Purchased by KBC Group NV

KBC Group NV grew its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 0.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,107,709 shares of the company’s stock after purchasing an additional 3,589 shares during the quarter. AbbVie makes up about 0.6% of KBC Group NV’s portfolio, making the stock its 26th biggest holding. KBC Group NV’s holdings in AbbVie were worth $205,614,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of ABBV. Brighton Jones LLC grew its holdings in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the period. Rice Hall James & Associates LLC increased its position in AbbVie by 9.3% during the first quarter. Rice Hall James & Associates LLC now owns 5,144 shares of the company’s stock worth $1,078,000 after purchasing an additional 437 shares during the last quarter. Hohimer Wealth Management LLC raised its stake in AbbVie by 23.4% during the first quarter. Hohimer Wealth Management LLC now owns 1,895 shares of the company’s stock worth $397,000 after purchasing an additional 359 shares during the period. Finally, Apollon Financial LLC acquired a new position in AbbVie in the 1st quarter valued at about $277,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Up 2.9%

Shares of NYSE ABBV opened at $225.06 on Wednesday. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The stock has a market cap of $397.76 billion, a PE ratio of 107.17, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The business has a 50-day moving average price of $223.67 and a 200 day moving average price of $203.22. AbbVie Inc. has a 52-week low of $163.81 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the prior year, the firm earned $3.00 EPS. AbbVie’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 524.24%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ABBV. Guggenheim raised their price target on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Erste Group Bank downgraded AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. BMO Capital Markets increased their price target on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. Cantor Fitzgerald set a $250.00 price objective on shares of AbbVie and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Finally, Daiwa America upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $236.57.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.